Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 176

1.

Arginase activity in the blood of patients with visceral leishmaniasis and HIV infection.

Takele Y, Abebe T, Weldegebreal T, Hailu A, Hailu W, Hurissa Z, Ali J, Diro E, Sisay Y, Cloke T, Modolell M, Munder M, Tacchini-Cottier F, Müller I, Kropf P.

PLoS Negl Trop Dis. 2013;7(1):e1977. doi: 10.1371/journal.pntd.0001977. Epub 2013 Jan 17. Erratum in: PLoS Negl Trop Dis. 2013 Jan;7(1). doi: 10.1371/annotation/9e89dee8-e2b7-4559-bd4e-933692403410.

2.

Arginase activity - a marker of disease status in patients with visceral leishmaniasis in ethiopia.

Abebe T, Takele Y, Weldegebreal T, Cloke T, Closs E, Corset C, Hailu A, Hailu W, Sisay Y, Corware K, Corset M, Modolell M, Munder M, Tacchini-Cottier F, Müller I, Kropf P.

PLoS Negl Trop Dis. 2013;7(3):e2134. doi: 10.1371/journal.pntd.0002134. Epub 2013 Mar 28.

3.

Atypical manifestations of visceral leishmaniasis in patients with HIV in north Ethiopia: a gap in guidelines for the management of opportunistic infections in resource poor settings.

Diro E, van Griensven J, Mohammed R, Colebunders R, Asefa M, Hailu A, Lynen L.

Lancet Infect Dis. 2015 Jan;15(1):122-9. doi: 10.1016/S1473-3099(14)70833-3. Epub 2014 Oct 7.

PMID:
25300862
4.
5.

Leishmania-HIV co-infection: clinical presentation and outcomes in an urban area in Brazil.

Cota GF, de Sousa MR, de Mendonça AL, Patrocinio A, Assunção LS, de Faria SR, Rabello A.

PLoS Negl Trop Dis. 2014 Apr 17;8(4):e2816. doi: 10.1371/journal.pntd.0002816. eCollection 2014 Apr. Erratum in: PLoS Negl Trop Dis. 2015 Mar;9(3):e0003653.

6.

Prevalence of malnutrition and associated risk factors among adult visceral leishmaniasis patients in Northwest Ethiopia: a cross sectional study.

Mengesha B, Endris M, Takele Y, Mekonnen K, Tadesse T, Feleke A, Diro E.

BMC Res Notes. 2014 Feb 4;7:75. doi: 10.1186/1756-0500-7-75.

7.

Development and external validation of a clinical prognostic score for death in visceral leishmaniasis patients in a high HIV co-infection burden area in Ethiopia.

Abongomera C, Ritmeijer K, Vogt F, Buyze J, Mekonnen Z, Admassu H, Colebunders R, Mohammed R, Lynen L, Diro E, van Griensven J.

PLoS One. 2017 Jun 5;12(6):e0178996. doi: 10.1371/journal.pone.0178996. eCollection 2017.

8.

Age-related alteration of arginase activity impacts on severity of leishmaniasis.

Müller I, Hailu A, Choi BS, Abebe T, Fuentes JM, Munder M, Modolell M, Kropf P.

PLoS Negl Trop Dis. 2008 May 14;2(5):e235. doi: 10.1371/journal.pntd.0000235.

9.

Visceral leishmaniasis treatment outcome and its determinants in northwest Ethiopia.

Welay GM, Alene KA, Dachew BA.

Epidemiol Health. 2016 Dec 28;39:e2017001. doi: 10.4178/epih.e2017001. eCollection 2016.

10.

Clinical characteristics and treatment outcome of patients with visceral leishmaniasis and HIV co-infection in northwest Ethiopia.

Hurissa Z, Gebre-Silassie S, Hailu W, Tefera T, Lalloo DG, Cuevas LE, Hailu A.

Trop Med Int Health. 2010 Jul;15(7):848-55. doi: 10.1111/j.1365-3156.2010.02550.x. Epub 2010 May 14.

11.

[Visceral leishmaniasis as an opportunistic infection. Case report and literature review].

Moradpour D, Markwalder K, Greminger P, Lüthy R.

Schweiz Rundsch Med Prax. 1990 Aug 2;79(31-32):921-6. Review. German.

PMID:
2203128
12.

Successful Treatment of Human Visceral Leishmaniasis Restores Antigen-Specific IFN-γ, but not IL-10 Production.

Adem E, Tajebe F, Getahun M, Kiflie A, Diro E, Hailu A, Shkedy Z, Mengesha B, Mulaw T, Atnafu S, Deressa T, Mathewos B, Abate E, Modolell M, Munder M, Müller I, Takele Y, Kropf P.

PLoS Negl Trop Dis. 2016 Mar 10;10(3):e0004468. doi: 10.1371/journal.pntd.0004468. eCollection 2016 Mar.

13.

Local increase of arginase activity in lesions of patients with cutaneous leishmaniasis in Ethiopia.

Abebe T, Hailu A, Woldeyes M, Mekonen W, Bilcha K, Cloke T, Fry L, Seich Al Basatena NK, Corware K, Modolell M, Munder M, Tacchini-Cottier F, Müller I, Kropf P.

PLoS Negl Trop Dis. 2012;6(6):e1684. doi: 10.1371/journal.pntd.0001684. Epub 2012 Jun 12.

14.

Microbial translocation induces an intense proinflammatory response in patients with visceral leishmaniasis and HIV type 1 coinfection.

Santos-Oliveira JR, Regis EG, Giacoia-Gripp CB, Valverde JG, Alexandrino-de-Oliveira P, Lindoso JÂ, Goto H, Oliveira-Neto MP, Guerra JO, Grinsztejn B, Jerônimo SB, Morgado MG, Da-Cruz AM.

J Infect Dis. 2013 Jul;208(1):57-66. doi: 10.1093/infdis/jit135. Epub 2013 Mar 28.

PMID:
23539743
15.

Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study.

Pintado V, Martín-Rabadán P, Rivera ML, Moreno S, Bouza E.

Medicine (Baltimore). 2001 Jan;80(1):54-73.

16.

Epidemiology of human immunodeficiency virus-visceral leishmaniasis-co-infection.

Naufal Spir PR, Zampieri D'Andrea LA, Fonseca ES, Prestes-Carneiro LE.

J Microbiol Immunol Infect. 2016 Apr;49(2):295-9. doi: 10.1016/j.jmii.2013.05.002. Epub 2013 Jul 6.

17.

Visceral leishmaniasis mimicking as second line anti retroviral therapy failure.

Yanamandra U, Jairam A, Shankar S, Negi R, Guleria B, Nair V.

Intern Med. 2011;50(22):2855-8. Epub 2011 Nov 15.

18.

Relapsing visceral leishmaniasis in a HIV-1 infected patient with advanced disease.

Standaert D, Laurent F, Jonckheere S, Scheiff JM, Vandercam B, Yombi JC.

Acta Clin Belg. 2013 Mar-Apr;68(2):124-7.

PMID:
23967722
19.

Pre- & post-treatment evaluation of immunological features in Indian visceral leishmaniasis (VL) patients with HIV co-infection.

Sinha PK, Bimal S, Singh SK, Pandey K, Gangopadhyay DN, Bhattacharya SK.

Indian J Med Res. 2006 Mar;123(3):197-202.

PMID:
16778304
20.

Serum chemokine profiles in visceral leishmaniasis, HIV and HIV/ visceral leishmaniasis co-infected Ethiopian patients.

Sisay Z, Berhe N, Petros B, Tegbaru B, Messele T, Hailu A, Wolday D.

Ethiop Med J. 2011 Jul;49(3):179-86.

PMID:
21991751

Supplemental Content

Support Center